Overview

* BIO-key Q3 2025 revenue declines to $1.55 mln, missing analyst expectations

* Company's Q3 net loss widens to $964,849 from $738,959 in Q3 2024

* BIO-key expects strong year-end, driven by European and Middle Eastern markets

Outlook

* BIO-key expects full-year 2025 revenue between $6.5 mln and $7 mln

* Company anticipates strong growth in 2026 driven by defense spending

* BIO-key plans cost reductions to support positive cash flow and profitability

Result Drivers

* REVENUE DECLINE - Decrease attributed to absence of large orders from two major customers in Q3'24

* SAAS MODEL IMPACT - Transition to SaaS model causes variability in revenue recognition

* DEFENSE SECTOR DEPLOYMENT - New deployment in Middle East defense sector expected to drive growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $1.55 $1.80

Revenue mln mln (1

Analyst)

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the electronic equipment & parts peer group is "buy"

* Wall Street's median 12-month price target for BIO-Key International Inc ( BKYI ) is $2.00, about 51.5% above its November 13 closing price of $0.97

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)